INTRODUCTION
Programmed cell death is executed through specific intracellular biochemical pathways. Apoptosis and necrosis are two common forms of programmed cell death that play essential roles in development and maintaining homeostasis in metazoan animals (Festjens et al., 2006) . Defects in apoptosis and necrosis have been implicated in the etiology of many forms of human diseases (Lockshin and Zakeri, 2007) .
Apoptosis is executed by a group of intracellular cysteine proteases, namely caspases (Thornberry and Lazebnik, 1998) . Upon caspase activation and subsequent cleavage of intracellular substrates, cells break into small membrane-wrapped vesicles known as apoptotic bodies (Kerr et al., 1972) . Necrosis, on the other hand, is associated with organelle swelling, cytoplasmic membrane breakdown, and ensuing inflammation responses (Festjens et al., 2006) .
Caspase activation during apoptosis is accomplished through two well-characterized pathways. The extrinsic pathway is activated through the binding of various death-inducing cytokines including TNF-a, TRAIL, and CD95 ligand to their respective receptors leading to the activation of caspase-8 (Peter and Krammer, 2003) ; The intrinsic pathway is activated after mitochondrial intermembrane space proteins such as cytochrome c and Smac/Diablo are released into the cytosol where they activate caspase-9 and relieve inhibition imposed by the Inhibitors of apoptosis proteins (IAPs), respectively (Li et al., 1997; Du et al., 2000; Verhagen et al., 2000) . Activated caspase-8 and caspase-9 subsequently cleave and activate several downstream caspases, including caspase-3 and caspase-7, which then cleave intracellular substrates, resulting in apoptosis.
These two pathways crosstalk through defined protein networks. The extrinsic apoptotic signal is amplified by the intrinsic pathway via the cleavage of Bid by caspase-8 (Li et al., 1998; Luo et al., 1998) . The truncated Bid, tBid, moves from the cytosol to mitochondria and causes the release of apoptogenic factors from mitochondria. On the other hand, Smac protein, once left mitochondria, induces the auto-degradation of cIAP1 and cIAP2, accelerating the formation of a RIPK1-containing caspase-8 activating complex in response to death receptor activation (Wang et al., 2008) .
Interestingly, the same apoptosis-inducing cytokines also cause necrosis in certain cell lines, especially when caspases are inhibited or cannot be activated efficiently (Laster et al., 1988; Vercammen et al., 1998a) . In mouse fibrosarcoma L929 cells for example, TNF-a prominently causes necrosis instead of apoptosis. In human T cell leukemia Jurkat cells that are defective in caspase-8 activation adaptor protein FADD, activation of TNF receptor or CD95 resulted in necrosis (Chan et al., 2003) . The mechanism of TNF-a-induced necrotic cell death is not well understood although both lysosomal and mitochondrial dysfunction have been implicated (Festjens et al., 2006) .
One essential protein in TNF-a, TRAIL, and CD95 ligandinduced necrotic cell death is RIPK1 (Holler et al., 2000) . RIPK1 is a multi-functional protein also known to mediate NF-kB and caspase-8 activation in response to TNF-a (Hsu et al., 1996; Kelliher et al., 1998; Petersen et al., 2007; Wang et al., 2008) . Although the kinase activity of RIPK1 is not required for NF-kB activation, such activity is crucial for both caspase activation and necrosis induction (Holler et al., 2000; Wang et al., 2008) .
The necrosis effector of RIPK1 is unknown. Neither is the relationship between RIPK1 kinase-dependent apoptosis and necrosis. Moreover, why certain cells such as L929 and Jurkat are able to undergo necrotic death in response to TNF-a family of cytokines while others solely commit to apoptosis remains a mystery.
Our laboratory has been studying cellular apoptotic pathways using a small molecule that mimics the function of Smac protein (Li et al., 2004) . Our study revealed that the Smac mimetic together with TNF-a, promote the formation of a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8 (Petersen et al., 2007; Wang et al., 2008) . During these studies, we noticed that the Smac mimetic-induced cell death in human colon cancer HT-29 cells could not be blocked by pan-caspase inhibitors as in many other types of cells. Instead, HT-29 cells underwent massive necrosis. A systematic analysis of this form of cell death using a combination of genome-wide siRNA screening and biochemical investigation revealed that a member of the receptor-interacting kinases, RIP3, is the key determinant for necrotic cell death downstream of RIPK1.
RESULTS
A Smac Mimetic Plus a Pan-Caspase Inhibitor Induce Necrosis in HT-29 Cells Smac mimetics have been shown to induce apoptosis in certain tumor cell lines (Petersen et al., 2007; Vince et al., 2007; Varfolomeev et al., 2007) , and death can be completely blocked with a pan-caspase inhibitor, z-VAD. Surprisingly, in HT-29 cells, exacerbated cell death occurred when cells were treated with Smac mimetic plus z-VAD ( Figures 1A and 1B) or another pancaspase inhibitor Q-VD-OPH ( Figure S1 ). Consistent with previous reports, both cIAP1 and cIAP2 in HT-29 cells underwent accelerated degradation upon Smac mimetic treatment ( Figure 1C ). Unlike apoptotic death, these dying cells showed positive propidium iodide (PI) staining ( Figure 1D ) and cell death was prevented by a necrosis specific chemical inhibitor, Necrostatin-1 (Figures 1A and 1B, Degterev et al., 2005) .
To verify that cell death seen in HT-29 cells was indeed necrosis, cells treated with either vehicle DMSO, or Smac mimetic plus z-VAD, were analyzed by electron microscopy (EM). While most of DMSO treated cells showed normal cellular morphology including intact cytoplasmic membranes ( Figure 1E-a displayed swelled mitochondria as well as discontinuous cytoplasmic membranes ( Figure 1E -b, c, d) . No obvious apoptotic morphological changes were observed.
Smac Mimetic Plus z-VAD Induced Necrosis Requires TNF-a and RIPK1
Since Smac mimetic induces apoptosis in certain tumor lines as a result of autocrine TNF-a (Petersen et al., 2007; Vince et al., 2007; Varfolomeev et al., 2007) , we checked whether autocrine TNF-a is required for the observed necrosis in HT-29 cells. Indeed, addition of an increasing amount neutralizing anti-TNF-a antibody to the culture medium blocked this form of cell death ( Figure 2A ). Consistently, knockdown of TNF receptor I also prevented these cells from dying ( Figures 2B and 2C ). Moreover, exogenously added TNF-a augmented Smac mimetic plus z-VAD induced cell death ( Figure 2D ) and it did so in a dose dependent manner ( Figure S2 available with this article online). Since RIPK1 is a critical mediator for TNF-a induced necrosis (Holler et al., 2000) , we also checked if the observed Smac mimetic-induced necrosis required RIPK1. As shown in Figures  2E and 2F , knockdown of RIPK1 almost abolished this form of cell death.
A Genome-Wide siRNA Screening Revealed RIP3 Is Critical for Necrosis The fact that Smac mimetic induced cell death requires both TNF-a and RIPK1 and that cell death was blocked by Necrostatin-1 indicated that such a form of cell death is similar to the previously described phenomenon of programmed necrosis or necropotosis (Holler et al., 2000; Lin et al., 2004; Degterev et al., 2008) . The finding that Smac mimetic drastically promoted z-VAD and TNF-a induced necrosis, however, offered us a more robust necrotic death system to further dissect the signaling pathway for necrosis.
We took advantage of this necrotic cell death model and performed a genome-wide siRNA screen using a Dharmacon human siRNA library consisting of 22,000 pools of four siRNA oligoes. Pools of siRNA were transfected into HT-29 cells cultured in 96-well plates, which were subsequently treated with TNF-a, Smac mimetic, and z-VAD. Exogenous TNF-a was added to increase the signal to noise ratio, and to rule out any siRNAs affecting TNF-a secretion. Cell viability was then measured and the ratio of viability between cells treated with these agents versus those treated with DMSO was scored. A siRNA oligo targeting RIPK1 was used as the positive control. As a validation to our screening strategy, the top hit with a score of 0.72 turned out to be RIPK1. The second best hit, with a score of 0.65, is another member of RIP kinase family, RIP3 ( Figure 3A ). RIP3 shares close similarity with RIPK1 at its N-terminal kinase domain and C-terminal RHIM domain through which it interacts with RIPK1 ( Figure 3A ; Sun et al., 1999 Sun et al., , 2002 Yu et al., 1999) . Unlike RIPK1, RIP3 does not have the death domain at its C terminus.
RIP3 and Its Kinase Activity Are Required for Necrosis but Not Apoptosis
To verify the role of RIP3 in necrosis, a cell line that stably expressed a shRNA targeting RIP3 was generated from the parental HT-29 cells. As shown in Figures 3B and 3C , compared to its parental cells, cells with RIP3 knockdown were resistant to necrosis. When RIP3 expression was restored with a shRNA resistant RIP3 transgene, cell death was re-established. However, if the transgene contains a K50A mutation known to abolish its kinase activity, cell death remained blocked. The observed difference in cell death was not due to changes in RIPK1 since its level remained the same in all four cell lines ( Figure 3C ).
We then tested whether RIP3 also has a role in apoptosis by measuring the cleavage of poly(ADP)ribose polymerase (PARP), a caspase-3/7 substrate, and cell survival rates between parental and RIP3 shRNA expressing HT-29 cells. No difference was seen in PARP cleavage or cell survival in these cells when apoptosis was induced by TNF-a plus Smac mimetic or cycloheximide ( Figures 3D and 3E ). In addition to TNF-a, Trail and CD95/Fas ligand have also been shown to be able to induce necrosis (Vercammen et al., 1998b; Holler et al., 2000) . To test whether RIP3 is also required for Trail and CD95-induced necrosis, we treated the same pair of parental and RIP3 shRNA expressing HT-29 cells with Trail/Smac mimetic/z-VAD or Fas ligand/Smac mimetic/z-VAD. As shown in Figure 3F , cell death induced by these agents was also completely eliminated in the RIP3 knockdown cells.
The Expression of RIP3 Correlates with Cellular Necrotic Response
To further confirm the role of RIP3 in TNF-a-induced necrosis, we treated 13 other cell lines with TNF-a, Smac mimetic, and z-VAD. We then measured cell viability and the level of RIP3 in these cell lines. As shown in Figures 4A and 4B , five cell lines including human T cell leukemia Jurkat and CCRF-CEM cells, human monocytic leukemia U937 cells, mouse fibrosarcoma L929 cells, and mouse embryonic fibroblasts (MEFs) responded to the treatment and underwent necrosis. All these cells ex- (E) T98G glioblastma cells were transfected with vector or plasmid DNA expressing wild-type RIP3 (WT-RIP3) or RIP3 kinase dead mutant (RIP3-K50A). Forty-eight hours posttransfection, cells were treated as indicated for another 48 hr. Cell viability was determined by measuring ATP levels. Data are represented as mean ± standard deviation of duplicates. Cell lysates were collected 48 hr posttransfection and aliquots of 20 mg were subjected to western blot analysis of RIP3, RIPK1 and b-actin levels. All experiments were repeated at least three times with similar results. pressed RIP3. On the other hand, human cervical cancer HeLa cell, breast cancer MCF-7 cell, osteosarcoma U2OS cell, glioblastoma T98G cell, pancreatic cancer Panc-1 cell, nonsmall cell lung cancer NCI-460 and H2009 cells, as well as embryonic kidney 293T cells did not express any detectable RIP3 and they did not undergo cell death upon these treatments. Unlike RIP3, RIPK1 was ubiquitously expressed in all these cells.
TNF-a induced necrosis has been most extensively studied in mouse fibrosarcoma L929 cells due to its unique ability to undergo necrosis in response to TNF-a, or z-VAD alone (Vercammen et al., 1998b; Degterev et al., 2005; Kim et al., 2007) . To test whether RIP3 is required for necrosis in this L929 cells, we knocked down RIP3 with three individual mouse siRNA oligoes. The result of one such oligo is shown in Figures 4C and 4D . Cell death induced by z-VAD, or TNF-a alone or combination of the two was attenuated when RIP3 was knocked down in L929 cells. The efficacy of necrosis blockage of these oligoes correlated with the efficiency of RIP3 knockdown ( Figures  S3A and S3B) . The levels of RIPK1 in L929 cells did not change after RIP3 was knocked down ( Figure S3B ). Similar to HT-29 cells, necrotic cell death in L929 cells was also accelerated by Smac mimetic in a concentration dependent manner ( Figure S3C ).
Since cells resistant to TNF-a induced necrotic death are also defective in RIP3 expression, we then tested whether ectopic expression of RIP3 converts these cells to sensitive ones. As shown in Figures 4E and 4F , when wild-type RIP3 was expressed in T98G cells at a sub-toxic level, we saw marked cell death in these cells upon necrosis induction compared to vector transfection controls. Expression of the kinase dead K50A mutant RIP3, however, did not cause cell death. Moreover, cell death in T98G cells resulted from RIP3 expression was blocked by the necrosis inhibitor, Necrostatin-1 but not caspase inhibitor zVAD, indicating that the observed cell death is necrosis. Similar effects were observed when RIP3 was expressed in HeLa cells, MCF-7 cells, and H2009 cells ( Figure S4 ).
RIP3 Kinase-Dead Mutant Dominant Negatively Regulates Necrosis
To study how RIP3 induce necrosis, we first tested whether the kinase dead mutant of RIP3 functioned as a dominant negative mutant by stably expressing the K50A mutant of RIP3 in HT-29 cells. Expression of RIP3 (K50A) at a level above the endogenous RIP3 blocked Smac mimetic/z-VAD or Smac mimetic/z-VAD plus TNF-a induced cell death ( Figures 5A and 5B) .
To verify the blockage of cell death was indeed due to the dominant negative effect of RIP3 K50A mutant expression, we designed siRNA that specifically knocked down the mutant form of RIP3. Indeed, knockdown of this kinase dead form of RIP3 restored the cell death response as long as the endogenous RIP3 remained intact ( Figures 5C and 5D) .
The dominant negative effect of RIP3 kinase dead mutant suggested that this protein might bind and sequester other signaling molecule in this necrosis pathway. The obvious candidate would be RIPK1. To test this directly, we immunoprecipitated RIP3 K50A from the HT-29 cells that stably expressed this transgene and the immune complex was analyzed by western blotting using an anti-RIPK1 antibody. As shown in Figure 5E , no RIPK1 was coprecipitated with the kinase dead RIP3 up to 8 hr of treatment with TNF-a alone, or TNF-a plus Smac mimetic or z-VAD. However, 4 hr after treatment of all three agents together, RIPK1 was found in the RIP3 K50A precipitate and the amount increased at 6 and 8 hr of treatment. The interaction between RIPK1 and RIP3 mutant was verified with reciprocal pull down with an anti-RIPK1 antibody ( Figure 5F ). Again, the two proteins interacted only when all three necrosis-inducing agents were present.
RIP3 Forms a Necrotic Complex with RIPK1
The dominant negative effect of kinase dead mutant RIP3 suggested that it might sequester RIPK1 and prevent its interaction with endogenous RIP3. To test whether endogenous RIP3 indeed interacts with RIPK1 upon necrosis induction, we treated HT-29 cells with TNF-a, Smac mimetic and z-VAD, followed by immunoprecipitation using an anti-RIPK1 antibody at different time points. Interestingly, an up-shift of RIP3 was observed after 4 hr of treatment and the shifted RIP3 continued to increase up to 8 hr ( Figure 6A, left panel) . Correlating with the shift, RIP3 was found in the RIPK1 immunocomplex starting at 4 hr of necrosis induction and peaked at 8 hr ( Figure 6A, right panel) . The up-shift Aliquots of 4 mg of cell lysates were immunoprecipitated with RIPK1 antibody or control IgG as described in the Experimental Procedures. The RIPK1 immunocomplex was eluted with acid in 60 ml volume and the whole elution was used to measure the levels of RIP3 and RIPK1 in the immunocomplex by western blot analysis. (B) HT-29 cells stably expressing flag-tagged wild-type RIP3 were treated as indicated for 8 hr. Aliquots of 1 mg of cell lysates were prepared for immunoprecipitation using an anti-Flag antibody. The levels of RIP3 and RIPK1 in the immunocomplex were determined by western blot analysis. (C and D) T98G cells were transfected with vector, or plasmid DNA expressing Flag-tagged wild-type RIP3 (WT-RIP3), RIP3 kinase dead mutant (RIP3-K50A), or RIP3-AAAA (residues 459-462 mutated to AAAA). Forty-eight hours posttransfection, cells were treated for 48 hr as indicated. Cell viability was determined by measuring ATP levels (C). Data are represented as mean ± standard deviation of duplicates. Cell lysates were collected and aliquots of 20 mg were subjected to western blot analysis of RIP3, RIPK1, and b-actin levels (D).
(E) HT-29 cells stably expressing flag-RIP3 were treated with DMSO/TNF-a (100 ng/ml)/Smac mimetic/z-VAD or Necrotatin-1/TNF-a/Smac mimetic/z-VAD. At the indicated time points, cell lysates were collected and aliquots of 500 mg total cell extracts were immunoprecipitated with an anti-caspase-8 antibody as described in Wang et al., 2008 . The caspase-8 immunocomplex was eluted with acid in 40 ml volume and the whole elution was used to measure the levels of flag-RIP3, RIPK1, caspase-8, and FADD by western blot analysis. All experiments were repeated at least two times with similar results.
of RIP3 and its interaction with RIPK1 only occurred under necrosis-inducing conditions ( Figure S5A ). The observed upshift of RIP3 is due to phosphorylation at the Ser199 site that depends on its own kinase activity. No such shift was observed in RIP3 K50A mutant protein when it was pulled down with RIPK1 ( Figures 5E and 5F ). Moreover, the RIP3 band can be shifted down to the original position on SDS-PAGE gel with a phosphatase treatment or a Ser199 to Ala mutation ( Figures S5B and  S5C ).
To further confirm the relevance of RIP3 up-shift and its induced interaction with RIPK1 to necrosis, HT-29 cells were cotreated with Necrostatin-1 during necrosis induction. As shown in Figure 6B , cotreatment with Necrostatin-1 completely prevented RIP3 up-shift as well as its interaction with RIPK1.
The importance of RIP3 and RIPK1 interaction for necrosis induction was verified with a mutation at the RHIM domain of RIP3 that is known to abolish its ability to interact with RIPK1 (Sun et al., 2002 ; Figure S6 ). Similar to the kinase dead mutant, introduction of this mutant protein was unable to render T98G cells responsiveness to the necrosis induction ( Figures 6C and 6D) .
Since RIPK1 forms a complex with caspase-8/FADD upon treatment with TNF-a plus Smac mimetic and the complex is stabilized by z-VAD (Petersen et al., 2007; Wang et al., 2008) , we wondered whether it is the same complex that recruits RIP3. To check that directly, we immunoprecipitated caspase-8 and analyzed the composition of the immunocomplex by western blotting. As shown in Figure 6E , RIP3 was found to associate with the RIPK1/FADD/caspase-8 complex after 4 hr of treatment. RIP3 continued to be recruited to the complex for up to 6 hr of treatment. Much less proteins were immunoprecipitated at 8 hr with this anti-caspase-8 antibody. This observation might reflect that a large percentage of cells were dying at this time point. When cells were cotreated with Necrostatin-1, none of these complexes were able to form efficiently. This is consistent with the notion that Necrostatin-1 inhibits RIPK1 kinase activity, which is required for the formation of RIPK1/FADD/caspase-8 complex Wang et al., 2008) .
To probe how RIP3 containing complex induces necrosis, we measured cellular localization of RIP3 in HT-29 cells before and after necrosis induction. RIP3 in resting cells is distributed in the cytosol ( Figure S7 ). Upon necrosis induction, it forms punctuated and filamentary dots and rods reminiscent of some kinds of organelle staining ( Figure S7 ). However, costaining with intracellular organelle markers, including mitochondria, nuclei, ER, Golgi, lysosomes, endosomes, and peroxisomes, did not show obvious colocalization ( Figure S7 ). It is therefore unlikely that the RIPK1/RIP3 necrosis complex simply destroys a cellular organelle by directly targeting it.
RIP3 Knockout Mice Showed Less Tissue Damage in a Cerulein-Induced Mouse Acute Pancreatitis Model
The fact that RIP3 is a critical mediator of TNF-a-induced necrosis, yet is dispensable in animal development allowed us to investigate this form of cell death in RIP3 knockout mice (Newton et al., 2004) . We reproduced RIP3 knockout mice as reported in Newton et al. and studied its role under pathological conditions in which necrotic cell death has been implicated ( Figure S8 ).
We first verified the importance of RIP3 in TNF-a-induced necrosis in embryonic fibroblasts (MEFs) prepared from embryos of RIP3-/+ mating. As shown in Figure 7A , MEFs from RIP3 knockout embryos did not contain any RIP3 protein while heterozygote MEFs had roughly half of RIP3 as in wild-type MEFs. RIPK1 level did not change in these cells. When these cells were treated with necrosis inducing agents including TNF-a/Smac mimetic/z-VAD or TRAIL/Smac mimetic/z-VAD, MEFs from the wild-type animal committed to death while cells from RIP3 knockout embryos did not ( Figure 7B ; Figures S9A  and S9B ). It is interesting to note that these MEFs were also quite resistant to Trail plus Smac mimetic induced apoptosis. However, the wild-type MEFs were readily killed when z-VAD was included ( Figure 7B ). In contrast, no difference in apoptosis was seen in RIP3 wild-type and knockout MEF when they were treated with TNF-a plus cycloheximide ( Figure S9C ), an observation that agrees with what was reported in the original RIP3 knockout paper (Newton et al., 2004) .
We chose cerulein-induced pancreatitis in mice to further study the role of RIP3 in this necrosis-associated disease model. Most cell death in the pancreas was found to be necrotic rather than apoptotic and the degree of necrosis correlates with severity of the disease (Mareninova et al., 2006) . Interestingly, when we analyzed the expression of RIP3 in different tissues from the cerulein-treated animals, we noticed a dramatic increase of RIP3 protein in the pancreas ( Figure 7C ). No such increase was seen in other tissues including liver, brain, spleen, and thymus. Twenty-four hours after the treatment, 8 out of 12 cerulein treated wild-type animals showed multiple areas of pancreas acinar cell loss and necrosis ( Figure 7D ). This effect was largely prevented in all RIP3 knockout littermates (n = 11). Consistently, serum amylase was elevated to higher levels in wild-type animals 24 hr after treatment of cerulein compared to those in the RIP3 knockout littermates ( Figure 7E ).
DISCUSSION
RIP3 Represents a Key Switch Point in the TNF-aInduced Cellular Apoptotic and Necrotic Pathways RIP3 had been an innocuous member of the RIP kinase family. Although ectopic expression of RIP3 in mammalian cells has been shown to cause apoptosis, such a phenotype could be the result of artificially high expression (Yu et al., 1999; Sun et al., 1999) . Indeed, knockout of RIP3 in mice did not cause any measurable defect in development, fertility, NF-kB activation, and apoptosis (Newton et al., 2004) . In contrast, the founding member of the RIP family, RIPK1, has critical roles in the above-mentioned signaling pathways and RIPK1 knockout mice die soon after birth (Kelliher et al., 1998; Holler et al., 2000; Petersen et al., 2007; Wang et al., 2008) .
The pro-apoptotic function of RIPK1 is to form a caspase-8 activation complex in response to TNF Receptor I activation (Wang et al., 2008) . This process starts with the accelerated degradation of cIAP1/2 induced by Smac protein (or Smac mimetics), and proceeds with release of RIPK1 from the TNFRI, deubiquitination of RIPK1 by the deubiquitin enzyme CYLD, and subsequent recruitment of FADD and caspase-8 to RIPK1 (Wang et al., 2008) . The activation of caspase-8 in this complex results in cleavage of RIPK1 by caspase-8 (Lin et al., 1999) . The cleavage of RIPK1 by caspase-8 potentially terminates necrotic signal.
The work presented here indicated that RIP3 is also recruited to the RIPK1 complex through direct interaction between the RHIM domains of RIPK1 and RIP3. If caspase-8 is inhibited after death receptor activation, RIP3 forms a stable complex with RIPK1/FADD/caspase-8 ( Figure 6E ) and transforms it to a pronecrosis complex. The necrosis blocker Necrostatin-1 efficiently prevents RIPK1/FADD/caspase-8 complex formation and subsequent recruitment of RIP3 to the complex ( Figure 6E ). Thus, apoptosis and necrosis induced by death inducing cytokines share a common biochemical pathway down to the step of RIPK1 activation following receptor activation, cIAP1/2 degradation, and deubiquitination of RIPK1 by CYLD. It is thus not surprising that CYLD is required for efficient RIPK1/FADD/caspase-8 complex formation (Wang et al., 2008) and scored as À/À mice as described in the Experimental Procedures. Cell lysates were collected and aliquots of 40 mg were used to measure for western blot analysis of RIP3, RIPK1, and b-actin levels.
(B) RIP3 +/+ or RIP3 À/À MEF cells were treated as indicated for 24 hr. Recombinant mouse TRAIL was used at 20 ng/ml. Cell viability was determined by measuring ATP levels. Data are represented as mean ± standard deviation of duplicates. Experiment was repeated at least three times with similar results.
(C-E) RIP3 knockout (n = 11) and wild-type littermate mice (n = 12) were given intraperitoneal injections of 50 mg/kg cerulein or saline once every hour for 10 hr. Fourteen hours after the last injection, mice were sacrificed and the samples of tissues and blood were harvested. The proteins were extracted from indicated tissues and subjected to western blot analysis of RIP3 and GAPDH levels (C). (D) The pancreatic tissue was stained with hematoxylin and eosin. The stained sections were examined by a pathologist in a blind fashion. Eight out of twelve cerulein treated wild-type animals showed multiple areas of pancreas acinar cell loss and necrosis while this effect was largely prevented in all RIP3 knockout littermates (n = 11). This effect is statistically significant (*p < 0.01).
(E) Serum amylase activity was measured using amylase assay kit. The result shown here are representative of five animals.
the top hit in a genome-wise siRNA screen in L929 cells for genes whose knockdown prevented TNFa-mediated necrosis (necropotosis) in these cells . The role of FADD in necrosis signaling seems cell type specific. The MEFs from FADD knockout mice are resistant to TNF-a-induced necrosis (Lin et al., 2004) while FADD null Jurkat cells underwent necrosis in response to TNF-a (Chan et al., 2003; Figures S10A and S10C) . The biochemical mechanism underlines such cell type specificity should be an interesting topic for future studies. Similar to HT-29 and L929 cells, the TNF-a-induced necrosis in FADD null Jurkat cells was also drastically accelerated by the Smac mimetic and the death was nearly abolished after RIP3 knockdown ( Figures S10C and S10D) . It is interesting to note that necrotic death in these cells does not require the presence of caspase inhibitors since there was no caspase-8 activation upon TNF-a/Smac mimetic treatment in contrast to wild-type Jurkat cells ( Figure S10B ).
The status of NF-kB also seems to affect cellular necrotic response to TNF-a/Smac mimetic/z-VAD. Blockage of NF-kB with an IKK inhibitor enhanced necrosis in HT-29 cells treated with these agents ( Figure S11 ). The mechanism of such enhancement should be another interesting topic for future studies.
Mechanism of RIP3-Dependent Necrotic Cell Death
It remains puzzling how RIP3/RIPK1 complex induces necrosis. Since RIP3 does not colocalize with all the major cell organelles examined ( Figure S7) , it is unlikely that the RIP3/RIPK1 pronecrotic complex directly destroy them. It is possible that this complex phosphorylates some specific cellular target(s) in a necrotic pathway. Identifying the unknown components of such a pathway should be an exciting topic for future studies.
Although not affected directly, mitochondria could be at least one of the targets in this pathway. Mitochondria are the center for energy production, Ca 2+ buffering, and ROS production. Malfunction of mitochondria will lead to collapse of the cell and thus necrosis. Indeed, in THP-1 cells, ANT, the mitochondrial ADP/ATP nucleotide exchanger, is locked into its cytosolic configuration and is unable to carry out ADP/ATP exchange when treated with TNF-a plus z-VAD (Temkin et al., 2006) . Inactivation of ANT stops oxidative phosphorylation-mediated ATP generation, resulting in depletion of cellular energy pools and necrotic cell death. Mitochondrial cyclophilin D, the regulator of ANT, might be a target of necrosis inducers. Consistently, MEFs from cyclophilin D knockout mice are partially resistant to TNF-a, Smac mimetic plus z-VAD induced cell death, although the resistance is not as complete as the RIP3 knockout MEFs ( Figure S12 ; Nakagawa et al., 2005) .
Reactive oxygen species (ROS) have been implicated in TNF-a-induced, RIPK1-dependent necrosis (Lin et al., 2004) . Nox1 NADPH oxidase has been shown to work downstream of RIPK1 to generate ROS in L929 and MEF cells (Kim et al., 2007) . However, ROS dependence seems cell-type specific. ROS quenching prevented necrosis in L929 cells but failed to do so in HT-29 cells treated with TNF-a, Smac mimetic, and z-VAD (data not shown). It seems that ROS is only required for one of branches of the RIP3-dependent necrosis pathway.
Physiological and Pathological Significance of Necrotic Death
Necrosis has often been associated with extreme physicalchemical injury. Although TNF-a, CD95 ligand, or TRAIL induced death receptor activation has been well documented to cause necrosis in certain cells, the significance of necrosis remains to be validated under physiological and pathological situations.
We tested the role of RIP3 in mouse models of ceruleininduced pancreatitis. Interestingly, although big differences between wild-type and RIP3 knockout mice were observed 24 hr after the first and 14 hr after the last cerulein injection, similar tissue damage was seen in these animals 10 hr after the first cerulein injection (data not shown), consistent with the idea that it is not the initial injury that is RIP3 dependent. More likely, the subsequent damages caused by the ensuing inflammatory response was eliminated in the pancreas of RIP3 knockout mice and the initial damage caused by the ceruleininduced leakage of pancreatic digestive enzymes had recovered. These results suggest that RIP3-dependent necrosis is part of a defense system against tissue injury caused by physical or chemical damage, and maybe more frequently, by microbe infections. Necrotic death could be an important way to eliminate damaged cells especially when caspases cannot be activated efficiently, like in FADD null Jurkat cells, or is blocked. Unlike apoptosis, necrosis amplifies the initial damage signal by activating inflammatory response, which further destroys the damaged cells and facilitates the clean up of cell debris. Not surprisingly, RIP3 expresses strongly in immunologic organs like thymus and spleen and its expression is induced during tissues injury ( Figure 7C) .
Other systems in which morphologically defined necrosis occur include T lymphocytes after HIV-1 infection and neutrophils/macrophages after bacterial infection (Festjens et al., 2006) . In these cases, viruses and bacteria often carry their own caspase inhibitors, and necrotic death may serve as an important defense mechanism to eliminate the microbes and solicit inflammation by releasing intracellular contents and/or cytokines.
Necrosis, when run in excess, could potentially cause irreversible tissue damage and death of the whole animal. Therefore, inhibition of RIP3 mediated necrosis with chemical inhibitors has the possibility to treat acute or chronic inflammation-related diseases such as pancreatitis.
EXPERIMENTAL PROCEDURES Reagents
The Smac mimetic compound was synthesized as described previously (Li et al., 2004) . Cycloheximide, propidium iodide, LPS, hematoxylin and eosin were obtained from Sigma. z-VAD and Q-VD-OPH were from Bachem and Calbiochem, respectively. Necrostatin-1 was purchased from Alexis Biochemicals. Human TNF-a monoclonal antibody and recombinant mouse TRAIL were from R&D Systems. Lambda Protein Phosphatase was from NEB. Amylase assay kit was from BioAssay Systems. The following antibodies were used for western blotting: RIPK1 (BD Biosciences, 610458), RIPK1 (Cell Signaling, 4926), Flag (Sigma, A8592), TNF-RI (Santa Cruz Biotech, SC-8436), PARP (Cell Signaling, 9542), caspase-8 (Cell Signaling, 9746), caspase-8 (BD Bioscience, 556466), mouse RIP3 (Prosci,XA-1023), FADD (Stressgen, AAM-212E), cIAP2(BD,552783), cIAP1(R&D,AF8181) and GAPDH (ab9486, Abcam). Human RIP3 polyclonal antibody was generated against full-length human RIP3 recombinant protein. GST-TNF-a (human) was generated as in Wang et al., 2008 . Recombinant human TRAIL protein was generated as previously described (Li et al., 2004) and recombinant human FasL was from Axxora.
Cell Culture
Human colon cancer HT-29, pancreatic carcinoma Panc-1, glioblastoma T98G, osteosarcoma U2OS, T cell leukemia CCRF-CEM, breast cancer MCF-7, HEK293T and mouse fibrosarcoma L929 cells were obtained from ATCC. Mouse embryonic fibroblasts (MEFs) were isolated from day 14.5-15.5 embryos. Jurkat leukemia cells were kindly provided by Dr. Adrian Ting of Mount Sinai School of Medicine and FADD null Jurkat was from ATCC. H2009 and NCI-460 nonsmall cell lung carcinoma cells were gifts from the laboratory of Dr. John Minna (UT Southwestern Medical Center at Dallas). Cyclophilin D +/+ and Cyclophilin D À/À MEFs were kindly provided by Dr. Yoshihide Tsujimoto of Osaka University. The culture conditions of these cells were described in the Supplemental Data.
Plasmids and siRNA Oligoes RIP3 cDNA was amplified by RT-PCR from total RNA of HT-29 cells with primers containing a C-terminal HA epitope and then cloned into a modified pCI-neo plasmid (Promega), which contains 3XFlag at the N-terminus. The RIP3 mutant cDNA constructs, RIP3-shRNA constructs, and siRNA oligoes were described in the Supplemental Data.
Cell Transfection and Immunofluorescent Staining
Transfection of cells with plasmid DNA or siRNA was performed according to the procedures described previously (Wang et al., 2008) . The transfection of siRNA oligos to I2.1 Jurkat cells was performed using Amaxa machine as described in Sun et al., 2004 (Supplemental References) . For Figure S7 , Flag-RIP3 expression stable cells were transfected with pDsRed2-Mito, pDsRed2-ER, pDsRed2-Peroxi, pDsRed-Golgi, pAcGFP1-Endo (Clontech) or GFP-LAMP1. Thirty hours posttransfection, cells were treated as indicated in figure legend and stained with mouse anti-flag antibody (Sigma). FITCconjugated or Rodamin-conjugated secondary antibody (Molecular Probe) was used. Cells were examined under a confocal microscopy (Zeiss 510).
RNAi Screening Procedure
Human genome-wide siRNA screening and analysis were described in the Supplemental Data.
Western Blot Analysis and Immunoprecipitation
The procedures for western blotting analysis and immunoprecipitation using antibodies against Flag, RIPK1, and caspase-8 were described in the Supplemental Data.
Generation of Stable Cell Lines
To generate RIP3 kinase-dead mutant expression cells, linearized plasmid DNA was transfected into HT-29 cells. Forty-eight hours post transfection, the cells were cultured in complete medium containing 2 mg/ml G418 (Calbiochem). After 4 weeks, clones were tested for expression of the transgene. For RIP3-shRNA expression cells, HT-29 cells were transfected with RIP3-shRNA construct and selected with 0.5 mg/ml puromycin (Calbiochem). The shRNAresistant scramble wild-type or kinase-dead version of RIPK1 expression construct was further introduced into RIP3-shRNA stable cells and colonies were selected with 2 mg/ml G418.
Generation of RIP3 Knockout Mice
The RIP3 knockout mice were generated as described previously (Newton et al, 2004) with minor modification ( Figure S8 ). The procedure used was described in the Supplemental Data.
Cerulein-Induced Pancreatitis
Male RIP3 deficient and wild-type littermate mice at 7-8 weeks of age were given intraperitoneal injections of 50 mg/kg cerulein (Sigma) once every hour for 10 hr. Animals were sacrificed 24 hr after the first injection and samples of tissues and blood were rapidly harvested. Quantification of pancreas injury was performed on pancreatic tissue sections stained with H&E and serum amylase activity.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supplemental References, and twelve figures and can be found with this article online at http://www.cell.com/supplemental/S0092-8674(09)00578-9.
